Table 2. Patients and treatment characteristics.

	EPNEC (N = 60)	SCLC (N = 82)	p
Age in years: median (range)	55.5 (23–81)	59 (35–81)	0.03
Gender Male Female	34 (56.7%) 26 (43.3%)	48 (58.5%) 34 (41.5%)	0.82
ECOG PS 0/1 PS 2/3	45 (75%) 15 (25%)	55 (67.1%) 27 (32.9%)	0.31
Smoking history	28 (46.7%)	81 (98.8%)	<0.001
Staging III IV	4 (6.7%) 56 (93.3%)	6 (7.3%) 76 (92.7%)	0.88
Ki67% (median, range)	50% (20–95%)	60% (7–100%)	0.86
Histology Small cell Large cell	49 (81.7%) 11 (18.3%)	82 (100%) —	<0.001
Tumour cell differentiation Well-differentiated Poorly differentiated	13 (21.7%) 47 (78.3%)	— 82 (100%)	<0.001
Type of first-line chemotherapy
- Platinum + etoposide	32 (53.3%)	80 (97.4%)	<0.001
- Platinum + irinotecan	20 (33.4%)	—
- Capecitabine + oxaliplatin	8 (13.3%)	—
- Cisplatin + gemcitabine	—	1 (1.2%)
- Carboplatin + paclitaxel	—	1 (1.2%)
Number of cycles (median, range)	5 (1–10)	5 (1–6)	0.76
Patients who received second line chemotherapy	32 (53.3%)	46 (56.1%)	0.70
Primary sites Pancreas Colorectal Stomach Oesophageal Cervical Bladder Nasopharyngeal Nasal Cavity Duodenum Hypopharyngeal Gallbladder Prostate Unknown primary site	16 (26.7%) 7 (11.7%) 5 (8.3%) 4 (6.7%) 4 (6.7%) 3 (5%) 3 (5%) 2 (3.3%) 2 (3.3%) 1 (1.7%) 1 (1.7%) 1 (1.7%) 11 (18.3%)	— — — — — — — — — — — — —